Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

BACKGROUND: Achievement of durable responses in patients with relapsed/refractory peripheral T cell lymphoma (PTCL) is challenging with current therapies, and there are few data regarding the potential benefits of continuing treatment in patients with the best response of stable disease (SD). Histon...

Full description

Saved in:
Bibliographic Details
Published in:J Hematol Oncol
Main Authors: Foss, Francine, Horwitz, Steven, Pro, Barbara, Prince, H. Miles, Sokol, Lubomir, Balser, Barbara, Wolfson, Julie, Coiffier, Bertrand
Format: Artigo
Language:Inglês
Published: BioMed Central 2016
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4785666/
https://ncbi.nlm.nih.gov/pubmed/26965915
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-016-0243-8
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items